



HUTCHISON CHINA MEDITECH

## Appointment of HSBC Bank plc as Joint Corporate Broker in London

**London: Friday, October 5, 2018:** Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has appointed HSBC Bank plc as its joint Corporate Broker in London with immediate effect. Panmure Gordon (UK) Limited will continue to act as joint Corporate Broker in London and Nominated Advisor to Chi-Med in London in respect of the AIM rules.

### About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: [www.chi-med.com](http://www.chi-med.com).

### Forward-Looking Statements

*This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.*

### CONTACTS

#### Investor Enquiries

Mark Lee, Senior Vice President,  
Corporate Finance & Development  
David Dible, Citigate Dewe Rogerson

+852 2121 8200

Xuan Yang, Solebury Trout

+44 7967 566 919 (Mobile)  
[david.dible@citigatedewerogerson.com](mailto:david.dible@citigatedewerogerson.com)  
+1 (415) 971 9412 (Mobile)  
[xyang@troutgroup.com](mailto:xyang@troutgroup.com)

#### Media Enquiries

**UK & Europe** – Anthony Carlisle, Citigate Dewe Rogerson

+44 7973 611 888 (Mobile)  
[anthony.carlisle@cdrconsultancy.co.uk](mailto:anthony.carlisle@cdrconsultancy.co.uk)

**Americas** – Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile)  
[bmiles@troutgroup.com](mailto:bmiles@troutgroup.com)

**Hong Kong & Asia ex-China** – Joseph Chi Lo, Brunswick

+852 9850 5033 (Mobile)  
[jlo@brunswickgroup.com](mailto:jlo@brunswickgroup.com)

**Mainland China** – Sam Shen, Edelman

+86 1367 179 1029 (Mobile)  
[sam.shen@edelman.com](mailto:sam.shen@edelman.com)

#### Nominated Advisor

Richard Gray / Andrew Potts, Panmure Gordon (UK) Limited

+44 (20) 7886 2500